Peptides for Strength Training Research

Strength research focuses on peptides that activate anabolic signalling pathways—primarily IGF-1 and growth hormone axes. Studies investigate direct IGF-1 analogues, GH-releasing peptides, and indirect modulators of muscle protein balance. Research contexts include cellular mechanotransduction, satellite cell activation, and whole-body hormonal adaptation in resistance-trained models.

IGF-1-LR3 research demonstrates potent myotrophic signalling in myoblast cultures and animal models, with dose-dependent increases in protein synthesis. CJC-1295/ipamorelin combinations show synergistic GH release in human studies. Follistatin-344 animal models indicate myostatin antagonism and lean mass gains, though human strength-specific data remain limited.

Human strength training studies with peptides are sparse; most data derive from hormone replacement or GH-deficiency contexts rather than athletic enhancement. Long-term safety and efficacy in trained populations are poorly documented. No large RCTs directly compare peptide plus training to training plus resistance-standard nutrition in strength athletes.

Strength-training peptides are not ARTG-registered for this indication. Research-grade compounds can be legally obtained for institutional study; personal use and non-prescriber access are outside TGA approval. Prescription access requires specific medical indication (e.g. GH deficiency) through an approved medical practitioner.